Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 05, 2023 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Present at Upcoming Healthcare Conferences

LEXINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
August 07, 2023 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

LEXINGTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
July 27, 2023 16:01 ET | Source: Keros Therapeutics, Inc.

Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

LEXINGTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors. The...
July 24, 2023 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension

Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug application to conduct a Phase 2 clinical trial of KER-012 in combination with...
June 12, 2023 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference

LEXINGTON, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
June 09, 2023 06:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association

Keros Therapeutics will be hosting a conference call and webcast today, June 9, 2023, at 8:00 a.m. Eastern time, to provide an update on its hematology franchise. LEXINGTON, Mass., June 09, 2023 ...
June 07, 2023 08:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare Conference

LEXINGTON, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
May 22, 2023 09:00 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

LEXINGTON, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
May 11, 2023 16:01 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association

LEXINGTON, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
May 04, 2023 16:01 ET | Source: Keros Therapeutics, Inc.

Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results

LEXINGTON, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery,...